Induction of insert-specific immune response in mice by hamster polyomavirus VP1 derived virus-like particles carrying LCMV GP33 CTL epitope

Virus Research

Volumn 163, Issue 1, 2012, Pages 2-10

  Mazeike, Egle ^a   Gedvilaite, Alma ^a   Blohm, Ulrike ^b  

^a VILNIUS UNIVERSITY   (Lithuania)

^b FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

Author keywords

CTL immune response; Hamster polyomavirus; Virus like particles

Indexed keywords

EPITOPE; MEGALIN; PROTEIN VP1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARENAVIRUS INFECTION; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG SYNTHESIS; HAMSTER POLYOMA VIRUS; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION; VIRUS LIKE AGENT; YEAST;

ANIMALS; ANTIGENS, VIRAL; ARENAVIRIDAE INFECTIONS; CAPSID PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DRUG CARRIERS; EPITOPES, T-LYMPHOCYTE; GLYCOPROTEINS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; POLYOMAVIRUS; RECOMBINANT FUSION PROTEINS; VACCINES, VIROSOME; VIRAL PROTEINS; VIRAL VACCINES;

HAMSTER POLYOMAVIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MIRIDAE; MUS;

EID: 84855584421     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2011.08.003     Document Type: Article

References (43)

1. Acierno P.M., Newton D.A., Brown E.A., Maes L.A., Baatz J.E., Gattoni-Celli S. Cross-reactivity between HLA-A2-restricted FLU-M1:58-66 and HIV p17 GAG: 77-85 epitopes in HIV-infected and uninfected individuals. J. Trans. Med. 2003, 1:3-7.
2. Aichele P., Kyburz D., Ohashi P.S., Odermatt B., Zinkernagel R.M., Hengartner H., Pircher H. Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(2):444-448.
3. Andreasson K., Tegerstedt K., Eriksson M., Curcio C., Cavallo F., Forni G., Dalianis T., Ramqvist T. Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors. Int. J. Cancer 2009, 124(1):150-156.
4. Bachmann M.F. Evaluation of lymphocytic choriomeningitis virus-specific cytotoxic T cell responses. Immunology Methods Manual 1997, 1921-1933. Academic Press Ltd., New York. I. Lefkovits (Ed.).
5. Battegay M., Cooper S., Althage A., Banziger J., Hengartner H., Zinkernagel R.M. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J. Virol. Methods 1991, 33:191-198.
6. Blohm U., Roth E., Brommer K., Dumrese T., Rosenthal F.M., Pircher H. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes. J. Immunol. 2002, 169(10):5522-5530.
7. Blohm U., Potthoff D., van der Kogel A.J., Pircher H. Solid tumors " melt" from the inside after successful CD8 T cell attack. Eur. J. Immunol. 2006, 36(2):468-477.
8. Brinkman M., Walter J., Grein S., Thies M.J., Schulz T.W., Herrmann M., Reiser C.O., Hess J. Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma. Cancer Immunol. Immunother. 2005, 54(6):611-622.
9. Buonaguro L., Racioppi L., Tornesello M.L., Arra C., Visciano M.L., Biryahwaho B., Sempala S.D., Giraldo G., Buonaguro F.M. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antiviral. Res. 2002, 54(3):189-201.
10. Da Silva D.M., Pastrana D.V., Schiller J.T., Kast W.K. Effect of pre-existing neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccine. Virology 2001, 290:350-360.
11. Den Hann J.M., Bevan M.J. Constitutive versus activation-dependent cross-presentation in immune complexity by CD8(+) and CD8(-) dendritic cell in vivo. J. Exp. Med. 2002, 196:817-827.
12. Ding F.X., Wang F., Lu Y.M., Li K., Wang K.H., He X.W., Sun S.H. Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 2009, 49(5):1492-1502.
13. Dorn D., Lawatscheck R., Zvirbliene A., Aleksaite E., Pecher G., Sasnauskas K., özel M., Raftery M., Schönrich G., Ulrich R., Gedvilaite A. Cellular and humoral immunogenicity of hamster polyomavirus-derived virus-like particles harboring a mucin 1 cytotoxic T-cell epitope. Viral Immunol. 2008, 21(1):12-27.
14. Gedvilaite A., Zvirbliene A., Staniulis J., Sasnauskas K., Krüger D.H., Ulrich R. Segments of puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice. Viral Immunol. 2004, 17(1):51-68.
15. Gedvilaite A., Dorn D.C., Sasnauskas K., Pecher G., Bulavaite A., Lawatscheck R., Staniulis J., Dalianis T., Ramqvist T., Schönrich G., Raftery M.J., Ulrich R. Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. Virology 2006, 354(2):252-260.
16. Gedvilaite A., Frommel C., Sasnauskas K., Burkhard M., Ozel M., Behrsing O., Staniulis J., Jandrig B., Scherneck S., Ulrich R. Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Virology 2000, 273(1):21-35.
17. Herbst-Kralovetz M., Mason H.S., Chen Q. Norwalk virus-like particles as vaccines. Expert Rev. Vaccines 2010, 9(3):299-307.
18. Hermans I.F., Daish A., Yang J., Ritchie D.S., Ronchese F. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res. 1998, 58:3909-3917.
19. Kalergis A.M., Ravetch J.V. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J. Exp. Med. 2002, 195(12):1653-1659.
20. Kang S.M., Yoo D.G., Lipatov A.S., Song J.M., Davis C.T., Quan F.S., Chen L.M., Donis R.O., Compans R.W., et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 2009, 4(3):e4667.
21. Keller S.A., Schwarz K., Manolova V., von Allmen C.E., Kinzler M.G., Bauer M., Muntwiler S., Saudan P., Bachmann M.F. Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation. Eur. J. Immunol. 2010, 40:103-112.
22. Kim S.K., Cornberg M., Wang X.Z., Chen H.D., Selin L.K., Welsh R.M. Private specificities of CD8 T cell responses control patterns of heterologous immunity. J. Exp. Med. 2005, 201:523-533.
23. Kundig T.M., Bachmann M.F., DiPaolo C., Simard J.J., Battegay M., Lother H., Gessner A., Kühlcke K., Ohashi P.S., Hengartner H., et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995, 268:1343-1347.
24. Lacasse P., Denis J., Lapointe R., Leclerc D., Lamarre A. Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. J. Virol. 2008, 82:785-794.
25. Lutz M.B., Kukutsch N., Ogilvie A.L., Rössner S., Koch F., Romani N., Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 1999, 223(1):77-92.
26. Martinez X., Regner M., Kovarik J., Zarei S., Hauser C., Lambert P.H., Leclerc C., Siegrist C.A. CD4-independent protective cytotoxic T cell induced in early life by a non-replicative delivery system based virus-like particles. Virology 2003, 305:428-435.
27. Nilges K., Höhn H., Pilch H., Neukirch C., Freitag K., Talbot P.J., Maeurer M.J. Human papillomavirus type 16, E7 peptide-directed CD8+ T cells from patients with cervical cancer and cross-reactive with the coronavirus NS2 protein. J. Virol. 2003, 75:5464-5474.
28. Ochsenbein A.F., Klenerman P., Karrer U., Ludewig B., Pericin M., Hengartner H., Zinkernagel R.M. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(5):2233-2238.
29. Ochsenbein A.F., Sierro S., Odermatt B., Pericin M., Karrer U., Hermans J., Hemmi S., Hengartner H., Zinkernagel R.M. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001, 411(6841):1058-1064.
30. Pircher H., Burki K., Lang R., Hengartner H., Zinkernagel R.M. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 1989, 342:559-561.
31. Pircher H., Moskophidis D., Rohrer U., Burki K., Hengartner H., Zinkernagel R.M. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 1990, 346:629-633.
32. Prevost-Blondel A., Zimmermann C., Stemmer C., Kulmburg P., Rosenthal F.M., Pircher H. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 1998, 161(5):2187-2194.
33. Prevost-Blondel A., Roth E., Rosenthal F.M., Pircher H. Crucial role of TNF-α in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J. Immunol. 2000, 164(7):3645-3651.
34. Pumpens P., Grens E. Artificial genes for chimeric virus-like particles. Artificial DNA: Methods and Applications 2002, 249-327. CRC Press LLC, Boca Raton. Y.E. Khudyakov, H.A. Fields (Eds.).
35. Ruedl C., Storni T., Lechner F., Bachi T., Bachmann M.F. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur. J. Immunol. 2002, 32:818-825.
36. Ruedl C., Schwarz K., Jegerlehner A., Storni T., Manolova V., Bachmann M.F. Virus-like particles as carriers for T-cell epitopes: inhibition of T-cell priming by carrier-specific antibodies. J. Virol. 2005, 79(2):717-724.
37. Sambrook J., Russell D. Molecular Cloning: A Laboratory Manual 2001, Cold Spring Harbor Laboratory Press, New York.
38. Sasnauskas K., Buzaite O., Vogel F., Jandrig B., Razanskas R., Staniulis J., Scherneck S., Krüger D.H., Ulrich R. Yeast cells allow the high-level expression and formation of polyomavirus-like particles. Biol. Chem. 1999, 380:381-386.
39. Schwarz K., Meijerink E., Speiser D.E., Tissot A.C., Cielens I., Renhof R., Dishlers A., Pumpens P., Bachmann M.F. Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur. J. Immunol. 2005, 35:816-821.
40. Speiser D.E., Miranda R., Zakarian A., Bachmann M.F., McKall-Faienza K., Odermatt B., Hanahan D., Zinkernagel R.M., Ohashi P.S. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 1997, 186(5):645-653.
41. Storni T., Bachmann M.F. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison. J. Immunol. 2004, 172:6129-6135.
42. Storni T., Lechner F., Erdmann I., Bächi T., Jegerlehner A., Dumrese T., Kündig T.M., Ruedl C., Bachmann M.F. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J. Immunol. 2002, 168(6):2880-2886.
43. Zvirbliene A., Samonskyte L., Gedvilaite A., Voronkova T., Ulrich R., Sasnauskas K. Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles. J. Immunol. Methods 2006, 11(1-2):57-70.